ArticleEmerging infectious diseases2020
Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.Human vaccines & immunotherapeutics · 2025Trial
- Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.Human vaccines & immunotherapeutics · 2023Trial
- Pneumococcal vaccination status in critically ill patients: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for elderly in Zhejiang province, China.Human vaccines & immunotherapeutics · 2026Article
- Risk factors for community-acquired pneumonia in older adults in Japan after the introduction of the childhood PCV13.BMC infectious diseases · 2026Article
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Management of the Diagnosis and Treatment of Pneumonia in an Aging Society.Internal medicine (Tokyo, Japan) · 2025Review
- Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis.Pneumonia (Nathan Qld.) · 2024Review
- Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines.Cureus · 2024Article
- Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.Emerging infectious diseases · 2024Article
- Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults.Pathogens (Basel, Switzerland) · 2023Review
- Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis.European clinical respiratory journal · 2023Review
- Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea.Scientific reports · 2022Article
- 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-TypeMicroorganisms · 2022Article
- Whole-Genome Analysis-Based Phylogeographic Investigation of Streptococcus pneumoniae Serotype 19A Sequence Type 320 Isolates in Japan.Antimicrobial agents and chemotherapy · 2022Article
- Distribution and Variation of Serotypes and Pneumococcal Surface Protein A Clades ofFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.